CPhI 2020
NOVENTURE SL will be present at CPhI together with FERRER. Arrange a meeting with us to learn more about our products and license availability in the different countries.
Contact us: https://noventure.com/contact-us
Pediatrics
0
euroPLX 74 Athens
NOVENTURE will be present at EuroPLX in Athens. Arrange a meeting with us to learn more about our products and license availability in the different countries.
TASECTAN® launched in Croatia by JGL
Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop.
TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and infants.
TASECTAN® is marketed in 40 countries with growing sales of more than two million packs per year (ex-factory, as reported by commercial partners).
TASECTAN® is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0373, Noventure SL).
